Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Summary

To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.

Timeline

Start

2019-12-04

Primary completion

2021-07-28

Completion

2021-07-28

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]”

Drugs

Indications